Table 2 FDA-approved DDR inhibitors in breast cancers in the past 5 years (2016–2021)
PARP inhibitors | Trial number | Disease setting | FDA approval | Approved mutation status | Study phase | Approved year |
|---|---|---|---|---|---|---|
Olaparib | NCT02000622 | Metastatic, gBRCA1/2-mutant, HER2-negative breast cancer after ≤ 2 prior lines of chemotherapy | Metastatic, HER2-negative breast cancers | BRCA1/2 mutations | III | 2018 |
Talazoparib | NCT01945775 | Advanced and/or metastatic HER2-negative breast cancer with germline BRCA1/2 mutation | HER2-negative locally advanced or metastatic breast cancer | Deleterious or suspected deleterious germline BRCA mutation | III | 2018 |